SCHEMBL7009532

SCHEMBL7009532

CCOC(=O)COc1ccc(C(=O)OCc2ccccc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.58
SLC6A2 P23975 1/20 0.58
SLC6A3 Q01959 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
LMNA P02545 2/20 0.57
HPGD P15428 3/20 0.55
RAB9A P51151 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
NPC1 O15118 1/20 0.55
MAPK1 P28482 1/20 0.55
ALDH1A1 P00352 3/20 0.55
MAPT P10636 2/20 0.55
GAA P10253 2/20 0.53
KDM4E B2RXH2 1/20 0.53
TP53 P04637 1/20 0.53
HSD17B10 Q99714 1/20 0.53
NPSR1 Q6W5P4 1/20 0.52
MAOB P27338 1/20 0.51
PLA2G4B P0C869 1/20 0.51
NR1H4 Q96RI1 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7370844 0.95 SMN1; SMN2 (0.55) KMT2ASLC6A2SLC6A3TDP1LMNA
SCHEMBL8625075 0.90 ALDH1A1 (0.59) LMNAHPGDRAB9ASMN1; SMN2NPC1
SCHEMBL2830303 0.88 KMT2A (0.59) KMT2ASLC6A2SLC6A3TDP1LMNA
SCHEMBL20830918 0.87 KMT2A (0.67) KMT2ASLC6A2SLC6A3TDP1LMNA
SCHEMBL6187602 0.87 NR1H4 (0.64) KMT2ALMNAHPGDRAB9ASMN1; SMN2
SCHEMBL5506784 0.87 KMT2A (0.55) KMT2ASLC6A2SLC6A3TDP1LMNA
SCHEMBL3493914 0.86 RAB9A (0.58) LMNAHPGDRAB9ASMN1; SMN2NPC1
SCHEMBL6941063 0.85 GAA (0.64) KMT2ATDP1LMNAHPGDALDH1A1
SCHEMBL340618 0.84 MAOB (0.67) KMT2ASLC6A2SLC6A3TDP1LMNA
SCHEMBL4500586 0.84 KMT2A (0.67) KMT2ASLC6A2SLC6A3TDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1224186-B1 PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION MILLENNIUM PHARM INC (US) 2003-09-24 EP disclosed
US-20030055244-A1 Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation MILLENNIUM PHARMACEUTICALS, INC. 2003-03-20 US disclosed
EP-1224186-A2 PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION COR THERAPEUTICS, INC. (US) 2002-07-24 EP disclosed
WO-2001030780-A2 PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION COR THERAPEUTICS, INC. (US) 2001-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055244-A1 Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation PF4, PFKP, FGB KMT2A 4716/4885SLC6A2 4839/4885SLC6A3 4504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.